Credit Suisse Ag Ironwood Pharmaceuticals Inc Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Credit Suisse Ag holds 197,789 shares of IRWD stock, worth $733,797. This represents 0.0% of its overall portfolio holdings.

Number of Shares

197,789

Previous 5,612,113 96.48%

Holding current value

$733,797

Previous $64.2 Million 97.32%

% of portfolio

0.0%

Previous 0.06%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$8.32 - $15.45 $45 Million - $83.7 Million	-5,414,324 Reduced 96.48%	197,789 $1.72 Million
Q4 2023 Feb 08, 2024	BUY	$8.79 - $11.51 $9.76 Million - $12.8 Million	1,110,544 Added 24.67%	5,612,113 $64.2 Million
Q3 2023 Nov 13, 2023	SELL	$8.25 - $11.35 $10.7 Million - $14.7 Million	-1,298,944 Reduced 22.39%	4,501,569 $43.4 Million
Q2 2023 Aug 11, 2023	BUY	$10.1 - $11.6 $6.35 Million - $7.29 Million	628,844 Added 12.16%	5,800,513 $61.7 Million
Q1 2023 May 10, 2023	SELL	$10.37 - $12.56 $301,082 - $364,667	-29,034 Reduced 0.56%	5,171,669 $54.4 Million
Q4 2022 Feb 13, 2023	BUY	$9.9 - $12.43 $5.52 Million - $6.93 Million	557,798 Added 12.01%	5,200,703 $64.4 Million
Q3 2022 Nov 10, 2022	BUY	$10.14 - $12.38 $2.24 Million - $2.74 Million	221,377 Added 5.01%	4,642,905 $48.1 Million
Q2 2022 Aug 12, 2022	SELL	$11.05 - $12.72 $480,896 - $553,574	-43,520 Reduced 0.97%	4,421,528 $51 Million
Q1 2022 May 16, 2022	SELL	$10.61 - $12.88 $1.71 Million - $2.08 Million	-161,535 Reduced 3.49%	4,465,048 $56.2 Million
Q4 2021 Feb 14, 2022	SELL	$10.86 - $13.95 $263,984 - $339,096	-24,308 Reduced 0.52%	4,626,583 $53.9 Million
Q3 2021 Nov 12, 2021	BUY	$11.92 - $13.92 $7.09 Million - $8.28 Million	594,844 Added 14.67%	4,650,891 $60.7 Million
Q2 2021 Aug 16, 2021	BUY	$10.16 - $13.11 $3.54 Million - $4.57 Million	348,217 Added 9.39%	4,056,047 $52.2 Million
Q1 2021 May 14, 2021	SELL	$9.04 - $11.86 $1.12 Million - $1.46 Million	-123,521 Reduced 3.22%	3,707,830 $41.5 Million
Q4 2020 Feb 12, 2021	BUY	$9.05 - $12.2 $1.56 Million - $2.1 Million	172,393 Added 4.71%	3,831,351 $43.6 Million
Q3 2020 Nov 13, 2020	SELL	$8.99 - $10.74 $384,151 - $458,930	-42,731 Reduced 1.15%	3,658,958 $32.9 Million
Q2 2020 Aug 12, 2020	BUY	$9.14 - $11.97 $2.52 Million - $3.3 Million	275,931 Added 8.05%	3,701,689 $38.2 Million
Q1 2020 May 13, 2020	BUY	$8.58 - $14.01 $3.11 Million - $5.08 Million	362,615 Added 11.84%	3,425,758 $34.6 Million
Q4 2019 Feb 12, 2020	SELL	$8.22 - $14.0 $2 Million - $3.41 Million	-243,779 Reduced 7.37%	3,063,143 $40.8 Million
Q3 2019 Nov 12, 2019	BUY	$8.59 - $10.96 $11.9 Million - $15.2 Million	1,385,005 Added 72.06%	3,306,922 $28.4 Million
Q2 2019 Aug 14, 2019	BUY	$9.8 - $12.89 $3.18 Million - $4.19 Million	324,714 Added 20.33%	1,921,917 $21 Million
Q1 2019 May 14, 2019	BUY	$8.27 - $12.73 $52,944 - $81,497	6,402 Added 0.4%	1,597,203 $21.6 Million
Q4 2018 Feb 13, 2019	BUY	$7.8 - $16.13 $1.65 Million - $3.42 Million	212,137 Added 15.39%	1,590,801 $16.5 Million
Q3 2018 Nov 13, 2018	BUY	$14.31 - $17.65 $917,471 - $1.13 Million	64,114 Added 4.88%	1,378,664 $25.5 Million
Q2 2018 Aug 14, 2018	SELL	$11.83 - $16.2 $2.75 Million - $3.77 Million	-232,863 Reduced 15.05%	1,314,550 $25.1 Million
Q1 2018 May 15, 2018	SELL	$11.13 - $13.63 $254,543 - $311,718	-22,870 Reduced 1.46%	1,547,413 $23.9 Million
Q4 2017 Feb 14, 2018	SELL	$12.16 - $14.58 $547 - $656	-45 Reduced -0.0%	1,570,283 $23.5 Million
Q3 2017 Nov 14, 2017	BUY	$12.07 - $14.87 $2.74 Million - $3.37 Million	226,752 Added 16.88%	1,570,328 $24.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,343,576	1,343,576 $25.4 Million

Others Institutions Holding IRWD

# of Institutions

235

Shares Held

162M

Call Options Held

11.2M

Put Options Held

9.1K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $568M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account